Wolfram Völker

Learn More
BACKGROUND Enzyme replacement therapy with recombinant alpha-galactosidase A reduces left ventricular hypertrophy and improves regional myocardial function in patients with Fabry disease during short-term treatment. Whether enzyme replacement therapy is effective in all stages of Fabry cardiomyopathy during long-term follow-up is unknown. METHODS AND(More)
BACKGROUND In this prospective follow-up study, the effect of myocardial fibrosis on myocardial performance in symptomatic severe aortic stenosis was investigated, and the impact of fibrosis on clinical outcome after aortic valve replacement (AVR) was estimated. METHODS AND RESULTS Fifty-eight consecutive patients with isolated symptomatic severe aortic(More)
BACKGROUND We studied whether lipid-lowering therapy with atorvastatin (target LDL cholesterol [LDL-C] <100 mg/dL) compared with a moderate treatment regimen that used other lipid-lowering drugs led to a lesser progression of atherosclerosis and to different changes in plaque echogenicity in patients with coronary artery disease. METHODS AND RESULTS This(More)
BACKGROUND Enzyme replacement therapy (ERT) has been shown to enhance microvascular endothelial globotriaosylceramide clearance in the hearts of patients with Fabry disease. Whether these results can be translated into an improvement of myocardial function has yet to be demonstrated. METHODS AND RESULTS Sixteen patients with Fabry disease who were treated(More)
AIMS The present study aims to compare the change of left ventricular deformation during dobutamine stress echocardiography (DSE) with the reference standard of invasive myocardial fractional flow reserve (FFR) to assess the haemodynamic significance of intermediate coronary lesions. METHODS AND RESULTS In 30 patients with an intermediate coronary artery(More)
A clinical study was conducted to evaluate the efficacy and safety of percutaneous coronary excimer laser angioplasty in 60 patients with coronary artery disease. Forty-nine patients had stable exertional angina, and 11 patients had unstable angina despite medical therapy. A novel 1.4-mm diameter catheter with 20 quartz fibers of 100-microns diameter each(More)
A novel 1.3 mm diameter laser catheter, consisting of 20 concentric 100 microns quartz fibres around a central lumen for a 0.35 mm flexible guide wire, was used to ablate atherosclerotic tissue in thirty patients with coronary artery disease. The laser catheter was coupled to an excimer laser delivering energy at a wavelength of 308 nm and a pulsewidth of(More)
In coronary angiography, a catheter's tip has to be directed through the aorta towards the ostium – the region where the coronary arteries arise. Due to the anatomical variation in different humans, there is no common catheter which can be used for all patients. Thus, in a trial and error procedure cardiologists find a catheter that fits to the patient's(More)
During coronary artery angiography, a catheter is used to inject a contrast dye into the coronary arteries. Due to the anatomical variation of the aorta and the coronary arteries in different humans, one common catheter cannot be used for all patients. The cardiologists test different catheters for a patient and select the best catheter according to the(More)